ClinicalTrials.gg

Program

cenegermin

Also written as “Cenegermin”, “cenegermin-bkbj” and “OXERVATE® 0.002%”.

Its studies are mostly in Dry Eye Syndromes · Optic Neuropathy, Ischemic · Conjunctivitis, Allergic · Corneal Diseases · Corneal Ulcer, led by Dompé Farmaceutici S.p.A.

Furthest: phase 4, since Jul 21, 20206 company-led studies, 2 open or runningNext primary completion: Sep 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Dompé Farmaceutici S.p.A62 open or runningphase 4since Jul 21, 2020Jul 21, 2020Sep 2027phase 3 · NCT07453888

Also a collaborator on its studies: dompe-us-inc.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jul 21, 2020First study: phase 4 study in Corneal DiseasesFirst studyNCT04485546 · 37 enrolled · United States
  2. Nov 15, 20212 phase 3 studies in Dry Eye SyndromesNCT05136170, NCT05133180
  3. May 8, 2024Phase 4 study in Corneal UlcerNCT06411145
  4. Mar 2, 20262 phase 3 studiesNCT07453888, NCT07519902

Ahead

  1. Sep 2027Primary completion: phase 3 study in Optic Neuropathy, IschemicNCT07453888
  2. Dec 2027Primary completion: phase 3 study in Conjunctivitis, AllergicNCT07519902

TargetBeta

“Neurotrophic tyrosine kinase receptor agonist”ChEMBL 37, by rule

Other programs on the same three targets

ProgramCompanyFurthest phaseStudies
taletrectinibruleNuvation Biophase 311
repotrectinibruleBristol-Myers Squibbphase 39

Studies

All 6 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07519902Conjunctivitis, Allergic · United States, Argentina, Czechia and more3RecruitingDec 2027150
NCT07453888Optic Neuropathy, Ischemic · United States, Australia, South Korea and more3RecruitingSep 2027272
NCT06411145Corneal Ulcer4WithdrawnNov 12, 20240
NCT05136170Dry Eye Syndromes · United States, Italy3CompletedMay 24, 202385
NCT05133180Dry Eye Syndromes · United States, Italy3CompletedSep 22, 2022104
NCT04485546Corneal Diseases · United States4CompletedSep 30, 202137

How it is read

Names in the registry

  • “Cenegermin”, 3 entries
  • “cenegermin-bkbj”, 1 entry
  • “OXERVATE® 0.002%”, 1 entry
  • “Oxervate”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.